This breakthrough technology provides a new standard of care for clinicians and breast cancer patients during surgical procedures.
This agreement greatly expands cancer patients' access to care as the Sentimag system can be used by all hospitals by eliminating the need for radioactive tracers.
The Sentimag system and its implantable magnetic seed, Magseed, guide surgeons to cancerous lesions easily and do not require the use of traditional surgical needle wires or radioactive seeds. Similarly, the Sentimag system and its injectable iron solution, Sienna, is a replacement for the radioactive tracer and blue dye used in sentinel lymph node biopsies.
"We are very excited to be the exclusive distributor of the Sentimag system in the United States and Canada," said Alain de Lambilly, President of Leica Biosystems Tissue Acquisition Solutions business.
"This technology represents a major advancement in breast cancer procedures for clinicians and helps to improve the overall standard of care received by patients everywhere. The Sentimag system fits in perfectly with our product portfolio and aligns with our mission of advancing cancer diagnostics, improving lives."
The agreement includes the Sentimag system, Magseed and Sienna in both the United States and Canada, pending regulatory approval within those markets.
The Sentimag system is approved in the U.S. and received its CE mark approval in 2010 and has already been used in over 14,000 breast care procedures across Europe.
"Leica Biosystems is a leader in breast care, with products like the Mammotome breast biopsy system," said Dr Eric Mayes, CEO of Endomag.
"We are truly thrilled for them to offer our products alongside theirs in the U.S. and Canada. They have a world-class team and genuinely share our passion for improving lives, so are a natural partner to improve the standard of cancer care for everyone, everywhere."
